OBJECTIVE. Due to lack of information in head-to-head trials that compare the effect of disease modifying treatments (DMT) in the health related quality of life (HRQoL) of patients with remittent recurrent multiple sclerosis (RRMS), the objective of this study was to perform a network meta-analysis that estimates the treatment effect between different approved DMTs.

METHODS: . A systematic review was carried out, in which there were included randomized clinical trials (RCTs) publishes in English or Spanish, that evaluated DMT in patients with RRMS, and that reported outcomes of HRQoL by generic or specific questionnaires. The research of information was developed in electronic databases like Pubmed, Cochrane library, and LILACS until October 29th 2021. The NMA was carried out in software R, by the package “netmeta”. The outcomes were analyzed by mean differences between groups.

RESULTS: . In total, 16,784 publications were identified, of which 12 were included in the qualitative synthesis, and 6 were included in the NMA. According to the data obtained, it was possible to develop 9 NMA analyzing the following questionnaires: EQ-5D, SF-36 and MSIS-29. Specifically, in the EQ-5D index analysis, daclizumab presented significant statistical difference vs placebo (mean difference: 0.05; 95% CI: 0.01 – 0.09), while no difference was observed between daclizumab, cladribine, interferon beta 1-a and alemtuzumab. When considering EQ-5D VAS, alemtuzumab, daclizumab and interferon beta 1-a presented significant differences vs placebo, and no statistical differences between the treatments.

CONCLUSIONS: . It was observed that the different DMT included in the NMA with various questionnaires, both specific and generic, present similar effect on HRQoL in patients with RRMS.